文献速递消化道肿瘤与早癌消化内镜

粪便免疫化学试验检测结直肠癌的分期特异性敏感性:系统综述与荟萃分析

Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该系统综述与荟萃分析纳入44项研究(92,447名参与者,含3,034例结直肠癌),评估粪便免疫化学试验(FIT)检测不同分期结直肠癌的敏感性。汇总敏感性为:I期73%(65%-79%),II期80%(74%-84%),III期82%(77%-87%),IV期79%(70%-86%);T1期敏感性仅40%(21%-64%),T3期83%(68%-91%)。FIT对II-IV期结直肠癌可检出约五分之四,但对I期尤其T1期敏感性显著较低,提示早期检测性能需改进。

要点

  • FIT对II-IV期结直肠癌敏感性约80%,但对I期仅73%。
  • T1期结直肠癌FIT敏感性低至40%,早期检出能力有限。
  • 分期特异性敏感性估计因病例数少而不精确。

核心结论

  • FIT可检出II-IV期约五分之四的结直肠癌,但对I期及T1期敏感性显著较低,早期检测性能有待提高。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Web of Science、Embase和Cochrane Library自建库至2019年6月14日的英文文献。
  • 纳入44项研究,共92,447名参与者,其中3,034例结直肠癌病例,以结肠镜检查为参考标准。
  • 采用双变量荟萃分析汇总不同分期及研究设置(筛查队列、有症状/诊断队列、病例对照研究)的敏感性。

主要发现

  • 所有研究合并的汇总敏感性(95%CI)为:I期73%(65%-79%),II期80%(74%-84%),III期82%(77%-87%),IV期79%(70%-86%)。
  • 按T分期,汇总敏感性从T1期的40%(21%-64%)到T3期的83%(68%-91%)不等。
  • 分别计算筛查队列、有症状/诊断队列和病例对照研究的分期特异性敏感性时,因病例数少而精确性低。

临床怎么用

  • FIT对II-IV期结直肠癌检测敏感性较高,但对I期尤其T1期敏感性低,临床解读阴性结果时需考虑分期相关假阴性可能。

局限性

  • 分期特异性敏感性估计因病例数少而精确性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fecal immunochemical tests (FITs) detect the majority of colorectal cancers (CRCs), but evidence for variation in sensitivity according to the CRC stage is sparse and has not yet been systematically synthesized. Thus, our objective was to systematically review and summarize evidence on the stage-specific sensitivity of FITs. METHODS: We screened PubMed, Web of Science, Embase, and the Cochrane Library from inception to June 14, 2019, for English-language articles reporting on the stage-specific sensitivity of FIT for CRC detection using colonoscopy as a reference standard. Studies reporting stage-specific sensitivities and the specificity of FIT for CRC detection were included. Summary estimates of sensitivity according to the CRC stage and study setting (screening cohorts, symptomatic/diagnostic cohorts, and case-control studies) were derived from bivariate meta-analysis. RESULTS: Forty-four studies (92,447 participants including 3,034 CRC cases) were included. Pooled stage-specific sensitivities were overall very similar but suffered from high levels of imprecision because of small case numbers when calculated separately for screening cohorts, symptomatic/diagnostic cohorts, and case-control studies. Pooled sensitivities (95% confidence intervals) for all studies combined were 73% (65%-79%) for stage-I-CRCs and 80% (74%-84%), 82% (77%-87%), and 79% (70%-86%) for the detection of CRC stages II, III, and IV, respectively. Even substantially larger variation was seen in sensitivity by T-stage, with summary estimates ranging from 40% (21%-64%) for T1 to 83% (68%-91%) for T3-CRC. DISCUSSION: Although FITs detect 4 of 5 CRCs at stages II-IV, the substantially lower sensitivity for stage-I-CRC and, in particular, T1 CRC indicates both need and potential for further improvement in performance for the early detection of CRC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Niedermaier T, Balavarca Y, Brenner H, et al. Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020. PMID: 31850933. doi:10.14309/ajg.0000000000000465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。